FGL2
| Fibrinogen-like 2 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||
| Symbols | FGL2 ; T49; pT49 | ||||||||||||
| External IDs | OMIM: 605351 MGI: 103266 HomoloGene: 4864 GeneCards: FGL2 Gene | ||||||||||||
| |||||||||||||
| RNA expression pattern | |||||||||||||
 | |||||||||||||
| More reference expression data | |||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 10875 | 14190 | |||||||||||
| Ensembl | ENSG00000127951 | ENSMUSG00000039899 | |||||||||||
| UniProt | Q14314 | P12804 | |||||||||||
| RefSeq (mRNA) | NM_006682 | NM_008013 | |||||||||||
| RefSeq (protein) | NP_006673 | NP_032039 | |||||||||||
| Location (UCSC) |
Chr 7: 77.19 – 77.2 Mb |
Chr 5: 21.37 – 21.38 Mb | |||||||||||
| PubMed search | |||||||||||||
Fibrinogen-like protein 2, also known as FGL2, is a protein which in humans is encoded by the FGL2 gene.[1][2]
Structure
FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds.[1]
Function
This protein may play a role in physiologic functions at mucosal sites.
FGL2 is a protein that exhibits pleiotropic effects within the body and is an important immune regulator of both innate and adaptive responses.[3] The protein exists as both a Type II transmembrane protein (with the carboxy terminus on the extracellular side of the plasma membrane) found on the surface of macrophages and endothelial cells and can be constitutively secreted by both CD4+ and CD8+ T cells.[3]
Variants
Membrane bound
Membrane bound FGL2 (mFGL2) exhibits a prothrombinase activity, resulting in fibrin deposition, vascular thrombosis and tissue inflammation within an affected tissue, largely contributing to the innate arm of immunity.[4] Through mFGL2’s actions of promoting vascular thrombosis and tissue inflammation, it has been implicated in the pathogenesis of viral-induced fulminant hepatitis in acute hepatitis B infections.[5] Hepatocellular necrosis ensues rapidly, due to the HBV nucleocapsid protein’s ability to markedly upregulate expression of the mFGL2 prothrombinase, leading to fibrin deposition within the vasculature networks that supply blood to the liver.[5]
Secreted
In addition to its constitutive secretion by CD4+ and CD8+ T cells, the secreted form of FGL2 (sFGL2) can be inducibly secreted by Foxp3+ CD4+ CD25+ T regulatory cells (Tregs). Such Treg cells play a vital role in dampening the immune response after the clearance of an infection to prevent sterile inflammation. These cells also play a fundamental role in maintaining self tolerance by suppressing the activation and expansion of self-reactive lymphocytes that may instigate autoimmunity.9 Through their roles in immune homeostasis, it has been shown that depletion of the Treg cell population in murine models for disease lead to enhanced immune responses to a variety of infectious agents including hepatitis C virus (HCV).10 Additionally, patients with a chronic HCV infection were shown to have higher counts of Treg cells in peripheral blood when compared with successfully treated or healthy controls.11
Secreted FGL2 (sFGL2) plays a role as a negative regulator of the Immune response. sFGL2 inhibits the adaptive immune response. Knockout mice for FGL2 have T cells that are hyperproliferative.[6] sFGL2 is capable of inhibiting the proliferation of T cells stimulated by alloantigens and this inhibition is alleviated by the addition of a monoclonal antibody against sFGL2’s fibrinogen-like domain (FRED).12 When the supernatants of these T cell cultures are analyzed, they showed a predominant Th2 type polarization with upregulated levels of expression of interleukin-4 (IL-4) and Interleukin-10 (IL-10).12 There are also downregulated levels of Th1-type cytokines such as interleukin-2 (IL-2) and interferon γ (IFN-γ).[6] This shows that sFGL2 largely inhibits the Th1 type response needed to activate cytotoxic lymphocytes to clear HCV infections. Additionally, sFGL2 can inhibit the maturation of immature dendritic cells (DCs) by preventing NF-κB translocation to the nucleus and subsequent expression of the co-stimulatory molecule CD80 and major histocompatibility complex II (MHC II).[6] Therefore, sFGL2 may contribute to the negative regulatory activity exhibited by Treg cells.
sFGL2 works to repress immune response through its FRED Domain. The immunosuppressive activity of sFGL2 has been localized to the C-terminal region containing the FRED domain. sFGL2’s FRED domain shares significant homology to the fibrinogen related domains of potent immunoregulatory molecules like cytotaxin and tenascin.12 This works to repress immune responses by binding to the inhibitory FC receptor, FCγRIIB. Furthermore, HCV’s core protein has been found to increase the levels of expression of sFGL2 and cause virus-specific CD4+ T lymphocytes to skew largely toward a Th2 lineage, allowing for the establishment of a chronic infection.13
Clinical significance
Human Fibrinogen-like protein 2 may be useful as a biomarker for responsiveness to antiviral therapy.[7]
References
- 1 2 "Entrez Gene: FGL2 fibrinogen-like 2".
- ↑ Rüegg C, Pytela R (July 1995). "Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein". Gene 160 (2): 257–62. doi:10.1016/0378-1119(95)00240-7. PMID 7642106.
- 1 2 Marazzi S, Blum S, Hartmann R, Gundersen D, Schreyer M, Argraves S, von Fliedner V, Pytela R, Rüegg C (July 1998). "Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes". J. Immunol. 161 (1): 138–47. PMID 9647217.
- ↑ Ghanekar A, Mendicino M, Liu H, He W, Liu M, Zhong R, Phillips MJ, Levy GA, Grant DR (May 2004). "Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection". J. Immunol. 172 (9): 5693–701. doi:10.4049/jimmunol.172.9.5693. PMID 15100314.
- 1 2 Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, Zhang J, Ma XZ, Yang XC, Gao JF, Liu H, Selzner N, Clark DA, Adeyi O, Phillips MJ, Gorczynski RR, Grant D, McGilvray I, Levy G (February 2009). "The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis". Hepatology 49 (2): 387–97. doi:10.1002/hep.22684. PMID 19085958.
- 1 2 3 Hancock WW, Szaba FM, Berggren KN, Parent MA, Mullarky IK, Pearl J, Cooper AM, Ely KH, Woodland DL, Kim IJ, Blackman MA, Johnson LL, Smiley ST (March 2004). "Intact type 1 immunity and immune-associated coagulative responses in mice lacking IFN gamma-inducible fibrinogen-like protein 2". Proc. Natl. Acad. Sci. U.S.A. 101 (9): 3005–10. doi:10.1073/pnas.0308369101. PMC 365735. PMID 14976252.
[12] Chan CW et al. "Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells." J Immunol. 2003 Apr 15;170(8):4036-44.
Further reading
- Dawson SJ, White LA (1992). "Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin.". J. Infect. 24 (3): 317–20. doi:10.1016/S0163-4453(05)80037-4. PMID 1602151.
- Rüegg C, Pytela R (1995). "Sequence of a human transcript expressed in T-lymphocytes and encoding a fibrinogen-like protein.". Gene 160 (2): 257–62. doi:10.1016/0378-1119(95)00240-7. PMID 7642106.
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K; et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Marazzi S, Blum S, Hartmann R; et al. (1998). "Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes". J. Immunol. 161 (1): 138–47. PMID 9647217.
- Yuwaraj S, Ding J, Liu M; et al. (2001). "Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant". Genomics 71 (3): 330–8. doi:10.1006/geno.2000.6444. PMID 11170750.
- Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Zeng L, Dai J, Ying K; et al. (2003). "Identification of a novel human angiopoietin-like gene expressed mainly in heart". J. Hum. Genet. 48 (3): 159–62. doi:10.1007/s100380300025. PMID 12624729.
- Scherer SW, Cheung J, MacDonald JR; et al. (2003). "Human chromosome 7: DNA sequence and biology". Science 300 (5620): 767–72. doi:10.1126/science.1083423. PMC 2882961. PMID 12690205.
- Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Ning Q, Sun Y, Han M; et al. (2005). "Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection". J. Immunol. 174 (11): 7403–11. doi:10.4049/jimmunol.174.11.7403. PMID 15905589.
- Liu T, Qian WJ, Gritsenko MA; et al. (2006). "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry". J. Proteome Res. 4 (6): 2070–80. doi:10.1021/pr0502065. PMC 1850943. PMID 16335952.
- Kimura K, Wakamatsu A, Suzuki Y; et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
- Zhu CL, Yan WM, Zhu F; et al. (2006). "Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B". World J. Gastroenterol. 11 (44): 6936–40. PMID 16437596.